Supernus and Indivior signed an all-stock merger agreement to form a CNS-focused company, combining neurological and psychiatric portfolios under the Supernus name. The deal is structured as a “merger of equals” and is expected to close in 2026 subject to regulatory approvals. As described by the parties, Indivior shareholders will receive Supernus shares based on an exchange ratio, with the combined company projecting significant cost synergies and aiming for improved financial flexibility to support research and development. Supernus’ portfolio includes FDA-approved therapies in Parkinson’s disease, while Indivior brings addiction and attention-deficit/hyperactivity and other CNS programs. The transaction adds another large-scale consolidation step in CNS therapeutics and could reshape competitive positioning across opioid use disorder and movement-disorder categories.